Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1
Molecules · 2026
DOI: 10.3390/molecules31020302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Takuya Otani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Near InfraRed Photo-ImmunoTherapy Research Institute, Kansai Medical University, Hirakata 573-1010, Osaka, Japan. Hauptthemen laut MEDLINE: B7-H1 Antigen, Immunotherapy, Peptides, Phototherapy. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, JST FOREST Program.
Abstract (Originalsprache)
Near-infrared photoimmunotherapy (NIR-PIT) has recently attracted attention as a highly selective cancer treatment, with good treatment outcomes observed from the only antibody-based drug currently available for clinical use. However, since only a single agent is currently used clinically and the development of new antibodies is costly, exploring other therapeutic modalities is important. In this study, we investigated a novel peptide-based PIT drug targeting programmed death-ligand 1 (PD-L1), which is overexpressed in many types of cancer. The WL12 peptide, which is known to bind to PD-L1, was conjugated with the photoabsorber IRDye700DX (IR700), and its usefulness was evaluated in vitro and in vivo. In therapeutic experiments on PD-L1-positive cells, NIR-PIT with WL12-IR700 induced PIT-like morphological changes in cells and reduced cancer cell viability in an NIR light dose- and drug concentration-dependent manner. In vivo experiments showed significant suppression of tumor growth and an extended overall survival rate. These results indicate that the developed peptide-based drug can be used for PD-L1-targeted NIR-PIT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Near InfraRed Photo-ImmunoTherapy Research Institute, Kansai Medical University, Hirakata 573-1010, Osaka, Japan.
ORCID-Profile: Naoya Kondo, Hirofumi Hanaoka
Förderung
- Japan Science and Technology Agency
- JST FOREST Program
Zitieren
APA
Otani, T., Kondo, N., Kanai, A., & Hanaoka, H. (2026). Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1. Molecules. https://doi.org/10.3390/molecules31020302
Vancouver
Otani T, Kondo N, Kanai A, Hanaoka H. Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1. Molecules. 2026. doi:10.3390/molecules31020302
BibTeX
@article{Otani2026,
author = {Otani, Takuya and Kondo, Naoya and Kanai, Ayaka and Hanaoka, Hirofumi},
title = {Development of a Peptide-Based Photoimmunotherapy Drug Targeting PD-L1},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31020302}
}
EUVIMED